Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Pipeline Review, H1 2016

  • ID: 3743748
  • Drug Pipelines
  • 45 pages
  • Global Markets Direct
1 of 6
Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Pipeline Review, H1 2016

Summary

‘Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Pipeline Review, H1 2016’, provides in depth analysis on Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) targeted pipeline therapeutics.

The report provides comprehensive information on the Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39)
- The report reviews Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) targeted therapeutics and enlists all their major and minor projects
- The report assesses Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6
List of Tables

List of Figures

Introduction

Report Coverage

Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) Overview

Therapeutics Development

Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Products under Development by Stage of Development

Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Products under Development by Therapy Area

Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Products under Development by Indication

Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Products under Development by Companies

Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Products under Development by Universities/Institutes

Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Companies Involved in Therapeutics Development

Dicerna Pharmaceuticals, Inc.

Phylogica Limited

Sorrento Therapeutics, Inc.

Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Drug Profiles

DCRM-1711 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JY-3094 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit c-Myc and mTOR for Chondrosarcoma and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target c-Myc for Multiple Myeloma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit c-Myc for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit c-Myc for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit c-Myc for Solid Tumors and Hematological Malignancies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit c-Myc for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Dormant Projects

Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Discontinued Products

Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Featured News & Press Releases

Dec 21, 2015: Dicerna Updates Progress on the Development of DCR-MYC for the Treatment of Solid Tumors

Dec 09, 2015: Combination therapy escalates potency of Phylogica peptides against MYC-driven cancer

Nov 16, 2015: Phylogica exceeds gold - standard for treatment of MYC - driven cancer

Jun 01, 2015: Dicerna Presents Preliminary Safety and Efficacy Data from DCR-MYC Phase 1 Study in Patients with Advanced Solid Tumors at the 2015 ASCO Annual Meeting

May 14, 2015: Dicerna Announces Expansion of Ongoing DCR-MYC Phase 1 Study to Evaluate Safety and Efficacy in Patients with Advanced Pancreatic Neuroendocrine Tumors (PNETs)

May 13, 2015: Dicerna to Present Interim Clinical Data from First DCR-MYC Phase 1 Study in Patients with Advanced Solid Tumors at the 2015 ASCO Annual Meeting

Feb 02, 2015: Dicerna Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Clinical Trial of DCR-MYC, an Investigational RNAi Therapeutic Targeting the MYC Oncogene, in Patients with Advanced Hepatocellular Carcinoma

Apr 16, 2014: Dicerna Pharmaceuticals Initiates Phase 1 Study of DCR-MYC in Patients with Solid Tumors and Hematological Malignancies

Apr 02, 2013: Dicerna Pharma Announces First Patent Grant In Japan To Dicer Substrate siRNA Molecules

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016

Pipeline by Phylogica Limited, H1 2016

Pipeline by Sorrento Therapeutics, Inc., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
According to our recently published report 'Myc Proto-Oncogene Protein – Pipeline Review, H1 2016'; Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) pipeline Target constitutes close to 8 molecules. Out of which approximately 4 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says; Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) Myc (c-Myc) protein encoded by Myc gene, a regulator gene that code for a transcription factor. The protein plays a role in cell cycle progression, apoptosis and cellular transformation. Myc protein is a transcription factor that activates expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases. It also acts as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 co-activator, it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication. Myc is a proto-oncogene and it often upregulates in many types of cancers. Myc over expression stimulates gene amplification presumably through DNA over-replication.

The report 'Myc Proto-Oncogene Protein – Pipeline Review, H1 2016' outlays comprehensive information on the Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 3 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
Dicerna Pharmaceuticals, Inc.
Phylogica Limited
Sorrento Therapeutics, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll